The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
about
IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceMechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastomaContribution of chaperones to STAT pathway signaling.Epidermal growth factor signaling in transformed cellsHeat shock protein 90 stabilizes nucleolin to increase mRNA stability in mitosisThe co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug designClient Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted MutantsMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionClathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabDegradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.In Vitro Anticancer Effect of Gedunin on Human Teratocarcinomal (NTERA-2) Cancer Stem-Like Cells.ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.UIM domain-dependent recruitment of the endocytic adaptor protein Eps15 to ubiquitin-enriched endosomes.Primary trastuzumab resistance: new tricks for an old drug.Roles for growth factors in cancer progression.Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.Extracellular molecules involved in cancer cell invasionTargeting signal transduction pathways in metastatic breast cancer: a comprehensive review.A growing family: adding mutated Erbb4 as a novel cancer targetWild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancerIn vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in ratsHsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabNew developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.Targeting Hsp90: small-molecule inhibitors and their clinical development.Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase.Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells.Flotillins in receptor tyrosine kinase signaling and cancer.Re-examining HSPC1 inhibitors.
P2860
Q24309891-748DA78D-9423-4A68-9532-07FB76D09B5FQ24607424-400EDE34-2F3A-4936-B768-8404504DA408Q27687561-BF67E925-6BD1-4843-AAC3-E119CB7EAB27Q28084034-4FAE02D8-D744-42CA-8E35-88EF15C7E0A9Q28394964-EA0E714D-A0D8-4095-B7D1-B56BBAC8ADB8Q28485166-DEDCBE82-57F4-4BBC-BF7E-76CC4DB86694Q28534499-AC23CA5F-1180-45BD-B14D-FFFAECB20A58Q28550576-A4A1F03B-11A7-4520-8E07-0ADEA4B70F12Q28829301-B3664EF5-5A56-4893-958A-99F894A85328Q30439237-8113B88E-0996-4ED7-BBD5-7ED61F853EB2Q30535295-C9D01DD7-DA41-4789-ABF0-5C5037155DE9Q30862407-A6B28E22-8FFF-42DC-BD61-229C72BE6FC8Q33527397-C4860AB3-F144-48FB-868D-AC807C6F380CQ33637919-FAB6D159-378F-48D4-94E9-DA7CA88DB98BQ33819816-7A2FE21B-1699-4EC6-A4AC-12F9B7C13681Q33820676-6E2F0B9F-F9D9-4C5B-AAA8-6B7799E2BE3CQ34156895-809BBDE3-05A6-4057-A387-62B43E9B8EE6Q34274663-6774BE12-A03A-4C94-9760-A2298C32039AQ34610251-73DE3E89-975F-4C5A-9AA6-DC1DE94AA980Q34705858-9A185A04-8F56-4590-9E13-4094A101AED0Q34852929-F4767C1F-151D-47B5-933E-AEFD6E086625Q35058437-923C907B-72B2-45FA-B59D-0CE21C02EA8CQ35237503-A76CD866-F882-40BE-8F80-EA368B84AB85Q35583942-887623EA-DD28-45BE-B768-AD166A6CA187Q36062442-6423C315-D3CE-4572-82CE-C6637B920666Q36200403-01BD752B-3C76-4957-A13F-C81B284EC9F0Q36318728-A4597C69-7025-463D-B33E-6D718839456BQ36498165-7189E26E-DCE6-4DAB-8BB9-7BB6482F2338Q36647014-9CBCA8B3-0885-40CA-BB80-0396B232BEB2Q36802340-B59F0355-2174-4A52-97FE-08CC04BD6A07Q37081037-071D3457-EF4A-4B10-98DB-DBF6293E21C4Q37114366-BB1AD3C2-DAA6-4AC3-ADE5-D2917009AF96Q37120694-C0C9D06D-ACC7-432B-AAF5-423B68563687Q37148772-59709BD0-FE47-4A27-8735-CA10453BA578Q37215989-9D9259AB-37E8-410D-9E4F-3124CE676F85Q37222845-10A2EC14-5DCB-40B8-BFD5-65C41BE9FED9Q37453413-F19B1E63-F11E-4330-9A3E-D4B968027F0AQ37639917-26F68BA7-0A7C-408F-9CFC-24EE7B80AD77Q37693615-13FE8221-19A7-4418-97E5-51A2671FAF2AQ38931732-43BDAF49-57C4-4030-B9C7-37E67C605A0D
P2860
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@ast
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@en
type
label
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@ast
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@en
prefLabel
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@ast
The achilles heel of ErbB-2/HE ...... pharmacological intervention.
@en
P1433
P1476
The achilles heel of ErbB-2/HE ...... r pharmacological intervention
@en
P2093
Bose S Kochupurakkal
Yosef Yarden
P50
P577
2004-01-01T00:00:00Z